Navigation Links
EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
Date:10/24/2007

E2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, unc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Experimental treatment for Ebola Virus Shows promising results in mice
8. Hormone Deficiency Results In Miscarriage
9. Gleevec gets hopeful results
10. Breast Implants May Interfere With The Interpretation Of Mammogram Results
11. DNA Testing For More Accurate Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... ... 2015 , ... Security Life Insurance Company of America, a ... of PrimeStar Individual Dental Insurance. Beginning now, enhancements include the expansion of our ... (MAC) and usual, customary and reasonable (UCR). , Whether consumers are looking ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women’s Excellence in Wellness, ... Lake Orion location. The special consists of 2 months of unlimited classes for just ... Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... ... 2015 , ... Chronic Neck Pain. Neck pain is no small ... the neck. Another 19% suffer from head, migraine, or facial pain, in some cases ... of American workers must deal with neck pain. Strategies for mitigating neck ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon ... 2nd creating a buzz of media attention. In an effort to spread the ... Tiffany Hendricks. , "These days many people are feeling overwhelmed by stress and ...
(Date:7/3/2015)... ... , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod ... . To be held from March 4th - 6th, the 2016 (a previous announcement ... Dallas. , Designed to take participants from the basic training and fundamentals of nasal ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... smoking greatly increases the risk that a blood vessel ... called an aneurysm which could be life-threatening if ... Stroke Association,s International Stroke Conference 2010. Researchers reported on ... project, a multinational collaboration funded by the National Institutes ...
... , , ... ... , , ... ...
... first one, number of teeth in first year , FRIDAY, ... in the first year of life have been identified by ... of 6,000 people in Finland and Britain who took part ... until adulthood. The scientists pinpointed five genes associated with the ...
... ... allows point-of-care workers to improve workflow and patient care. , ... (PRWEB) February 26, 2010 ... partnership with Voalt , a leading developer of innovative point-of-care communications software ...
... ... patients and asbestos exposure victims who are interested in learning more about clinical trials ... ... provide comprehensive resources for mesothelioma patients and their loved ones, including information about ...
... ... the public to spend two moonlit evenings basking in blissful meditations and looking at ... ... opportunity to explore life,s most fascinating questions at a most unexpected place, Tampa,s USF ...
Cached Medicine News:Health News:Smoking significantly increases risk of aneurysm in people with certain genes 2Health News:Smoking significantly increases risk of aneurysm in people with certain genes 3Health News:Landauer, Inc. Declares Regular Cash Dividend 2Health News:Genes Behind Tooth Development Discovered 2Health News:Connexall Announces Partnership with Voalt 2Health News:Connexall Announces Partnership with Voalt 3Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 2Health News:Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options 3Health News:Explore, Love, Happiness, Life Purpose, and Destiny with World Renowned Yogi and Mystic, Sadhguru 2
(Date:7/6/2015)...  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... from the Company,s Board of Directors in order to ... of Impax in 1995 and served as the Company,s ... April 2014. Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO ... Chief Executive Officer stated, "We wish to thank Larry ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Rochester Medical Corporation (NASDAQ: ROCM ) will announce ... 2012.  The Company will then hold a quarterly conference call ... 3:30 p.m. central time (4:30 p.m. eastern time). ... be accessed at Rochester Medical,s website at www.rocm.com .  ...
...   Hospira, Inc. (NYSE: HSP ), the ... announced enrollment of the first patient in a Phase III ... III program, which follows a successful Phase I trial that ... EPO and the reference product, Amgen,s Epogen ® in ...
Cached Medicine Technology:Rochester Medical Announces First Quarter 2012 Earnings Conference Call, Wednesday, January 25, 2012 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 2Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 3
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: